AlgoTx develops novel solutions for complex pain. Our lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan disease erythromelalgia.
Location: France, Ile-de-France, Suresnes
Employees: 11-50
Total raised: $21.25M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 31.03.2021 | Omnes Capi... | omnescapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.03.2023 | Series B | $21.25M | - |
Mentions in press and media 3
| Date | Title | Description |
| 16.03.2023 | France-based AlgoTx raises EUR 20 million in funding | Suresnes, a France-based biotech-company developing treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), AlgoTx raised EUR 20 million in Series B. The round took place on March 14, 2023. Relyens Innovation Santé / Turenne ... |
| 15.03.2023 | AlgoTx Raises €20M in Series B Funding | AlgoTx, a Suresnes, France-based biotech-company developing treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), raised €20M in Series B funding. The round was led by Relyens Innovation Santé / Turenne Capital, with partic... |
| - | AlgoTherapeutix | “AlgoTx – Simple solutions for complex pain” |